Option chain shows key data for Brookfield Finance Inc. 4.625% Subordinated Notes due October 16, 2080's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Brookfield Finance Inc. 4.625% Subordinated Notes due October 16, 2080.

Brookfield Finance Inc. 4.625% Subordinated Notes due October 16, 2080 (NYSE:BNH) Stock, Option Chain

Brookfield Finance Inc. 4.625% Subordinated Notes due October 16, 2080

Bonheur ASA

Financial giants have made a conspicuous bullish move on Lemonade. Our analysis of options history for Lemonade (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMND#NYSE">LMND</a>) revealed 20 unusual trades.
Delving into the details, we found 70% of traders were bullish, while 20% showed bearish tendencies. Out of all the trades we spotted, 11 were puts, with a value of $1,950,705, and 9 were calls, valued at $1,190,845.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $15.0 to $55.0 for Lemonade during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Lemonade's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Lemonade's substantial trades, within a strike price spectrum from $15.0 to $55.0 over the preceding 30 days.
<h3>Lemonade Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732295755_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LMND</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/29/24</td>
<td>$4.6</td>
<td>$3.7</td>
<td>$4.3</td>
<td>$49.00</td>
<td>$460.2K</td>
<td>5.0K</td>
<td>1.2K</td>
</tr>
<tr>
<td>LMND</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/29/24</td>
<td>$4.1</td>
<td>$3.6</td>
<td>$3.8</td>
<td>$49.00</td>
<td>$440.0K</td>
<td>5.0K</td>
<td>2.7K</td>
</tr>
<tr>
<td>LMND</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$38.6</td>
<td>$38.5</td>
<td>$38.6</td>
<td>$15.00</td>
<td>$386.0K</td>
<td>84</td>
<td>275</td>
</tr>
<tr>
<td>LMND</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$38.7</td>
<td>$38.6</td>
<td>$38.7</td>
<td>$15.00</td>
<td>$263.1K</td>
<td>84</td>
<td>275</td>
</tr>
<tr>
<td>LMND</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/29/24</td>
<td>$2.65</td>
<td>$2.55</td>
<td>$2.55</td>
<td>$48.00</td>
<td>$250.5K</td>
<td>91</td>
<td>3.6K</td>
</tr>
</tbody>
</table>

<h3>About Lemonade</h3>
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes. The company is using technology, data, artificial intelligence, contemporary design, and social impact to deliver delightful and affordable insurances. Geographically, it operates in California, Texas, New York, New Jersey, Illinois, Georgia, Washington, Colorado, Pennsylvania, Oregon and others.
<h3>Present Market Standing of Lemonade</h3>
<ul>
<li>With a volume of 2,396,176, the price of LMND is up 0.08% at $50.4. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 95 days.</li>
</ul>
<h3>Expert Opinions on Lemonade</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $33.4.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Piper Sandler persists with their Neutral rating on Lemonade, maintaining a target price of $44. 
&#x2A; Maintaining their stance, an analyst from Piper Sandler continues to hold a Neutral rating for Lemonade, targeting a price of $25. 
&#x2A; An analyst from Morgan Stanley persists with their Underweight rating on Lemonade, maintaining a target price of $23. 
&#x2A; An analyst from BMO Capital persists with their Underperform rating on Lemonade, maintaining a target price of $15. 
&#x2A; Consistent in their evaluation, an analyst from JMP Securities keeps a Market Outperform rating on Lemonade with a target price of $60. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Lemonade options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Markets

LMND

Behind the Scenes of Lemonade's Latest Options Trends

Institutional investment in the cryptocurrency space is poised for a massive influx, with hundreds of billions of dollars expected to <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42138947/bitcoin-zeroes-in-on-100000-but-this-indicator-signals-one-more-brief-correction">enter the market</a> in the coming years, according to Devin Ryan, managing director at JMP Securities.
What Happened: In an <a href="https://www.cnbc.com/video/2024/11/22/crypto-boom-drives-investment-opportunities-with-coinbase-and-robinhood-leading-the-charge.html">interview</a> with CNBC, Ryan emphasized that the evolving regulatory landscape and the increasing acceptance of Bitcoin exchange-traded funds (ETFs) are key catalysts for this transformative growth.
"We have research out saying $220 billion of assets are coming into Bitcoin ETFs in the next three years," Ryan said. "If there is a strategic reserve, that could be hundreds of billions of dollars of assets into Bitcoin."
Ryan pointed out that trading volumes for companies like Coinbase Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) and Robinhood (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) have surged since the U.S. presidential election. 
Coinbase volumes, for instance, have tripled, reflecting growing interest in the sector. 
"This activity unlocks a lot of innovation that's been held back," Ryan said, noting the potential for significant growth in payments, remittances, stablecoins, and Web3 applications.
Sarah Kunst, managing director at Cleo Capital, echoed Ryan's optimism, noting that institutional money has been waiting on the sidelines for regulatory clarity. 
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42138209/microstrategy-trading-at-insane-256-premium-to-bitcoin-holdings-research-shows">MicroStrategy Trading At &#8216;Insane&#8217; 256% Premium To Bitcoin Holdings, Research Shows</a>
Kunst highlighted the new U.S. administration&#8217;s potentially more favorable stance toward mergers and acquisitions (M&amp;A) as a driver for ecosystem growth. 
"I think there are people who have not yet gotten in the game who want to get in the game," she said. "This is really crypto's third act."
Kunst identified key players in the space, including crypto exchanges and infrastructure firms, as potential acquisition targets for larger financial institutions. 
"Names like FalconX, the crypto prime brokerage, and Gemini, the crypto marketplace, are likely to attract attention from big acquirers," she stated.
While Bitcoin CRYPTO: BTC) remains the centerpiece of institutional interest, Kunst sees a broadening investment focus. "Meme coins are dangerous—you can make a lot, but you can lose your shirt," she warned. 
Instead, she pointed to stablecoins and cryptocurrency ETFs as safer options, especially for institutions unable to hold crypto directly.
Ryan reinforced this outlook, emphasizing the importance of capital flows. 
"Follow the flows, and the flows are still coming—we're in the early days," he said. 
Beyond Bitcoin ETFs, Ryan expects tens of billions of dollars to flow into other crypto tokens as regulatory uncertainty diminishes, spurring innovation and further investment in the space.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42136031/charles-schwab-prepares-for-spot-cryptocurrency-trading-under-new-leadership">Charles Schwab Prepares For Spot Cryptocurrency Trading Under New Leadership</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

$BTC

COIN

HOOD

Bitcoin ETFs Will See Hundreds Of Billions In Inflows, Analyst Predicts

Shaquille O&#8217;Neal is one of the most famous and successful people around, but when it comes to his fortune, he&#8217;s surprisingly relaxed about it. On a recent Dan Patrick Show, Dan asked the NBA legend if he's a billionaire yet and his response was classic Shaq. He casually replied, &#8220;I don&#8217;t know, I never checked.&#8221;
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/advisor-adv-warren-buffett">Warren Buffett Flipped His Neighbor's $67,000 Life Savings Into A $50 Million Fortune — This Would Be Worth Over $500 Million Today</a></li>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
<li><a href="https://www.benzinga.com/money/cd-valet-growth">CD Popularity Soars: Over 50 Million Americans Embrace Safe Savings with 5–10% Annual Growth</a></li>
</ul>
Instead of closely monitoring his bank balance like many other wealthy individuals, Shaq measures wealth differently. To him, being rich isn't about hitting a specific dollar amount but about being able to take care of his family – <a href="https://www.benzinga.com/personal-finance/24/10/41186647/nba-star-shaq-wanted-to-get-rich-to-buy-his-mother-anything-she-wanted-that-right-there-is-what-">especially his mom</a>.
When a kid recently asked Shaq how it feels to be rich, he gave a heartfelt answer: &#8220;My definition of rich is being able to buy my mother whatever she wants – my favorite person in the world.&#8221; For Shaq, taking care of his mother, who made countless sacrifices when he was growing up, is the ultimate sign of wealth.
In the interview, Shaq recalled moments he'd never forget – <a href="https://www.benzinga.com/personal-finance/24/10/41337452/nba-legend-shaq-was-raised-by-teen-mom-who-fueled-his-success-cant-outplay-me-because-if-you-are">seeing his mom struggle</a>, even wearing the same pair of pants multiple days a week just to make ends meet. That's why, when he started making money, one of his first goals was to ensure his mom never had to struggle again. She was the first person he thought of when he got his big NBA paycheck.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">.<a href="https://twitter.com/SHAQ?ref_src=twsrc%5Etfw">@Shaq</a> shares what his definition of being "rich" is. <a href="https://t.co/5ydPVEhGfB">pic.twitter.com/5ydPVEhGfB</a>
&mdash; Dan Patrick Show (@dpshow) <a href="https://twitter.com/dpshow/status/1857147741824278590?ref_src=twsrc%5Etfw">November 14, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: ‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a>
Shaq's motivation comes from seeing his mom's sacrifices and ensuring she's always comfortable. "As long as my mother doesn't have to feel like she felt when we were young, that's my definition of being rich," he said.
Shaq's big heart doesn't stop with his mom. He shared a recent story about being at Walmart, where he spotted a mom with a tall son and three young daughters. The mom was picking out items for her kids and Shaq approached her, asking how much she planned to spend. After learning she was buying only what she could afford, he gave her $5,000 to get everything she needed for her family. Moments like these show what matters most to Shaq – using his money to make life better for others.
Shaq also wants his kids to learn these values. He wants them to understand that just because he has a lot of money doesn't mean they can rely on it without effort. For this reason, he has made it clear that his children must earn a share of his money by becoming good students, <a href="https://www.benzinga.com/personal-finance/24/11/41869301/shaqs-got-a-500-million-fortune-but-his-kids-arent-getting-a-dime-without-earning-it-you-need-3-degrees-to-touch-daddys-cheese">getting multiple diplomas</a> and demonstrating their ability to work hard on their own.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
<li>Studies show 50% of consumers think Financial Advisors cost much more than they do —<a href="https://www.benzinga.com/money/money-pickle"> to debunk this, this company provides matching for free and a complimentary first call with the matched advisor.</a></li>
</ul>

Personal Finance

Shaquille O'Neal Says He Doesn't Know If He's A Billionaire Yet – 'I Never Checked.' Here's What Being Rich Means To Him

Morgan Stanley analyst Stephen Byrd maintains American Electric Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEP#NASDAQ">AEP</a>) with a Overweight and lowers the price target from $109 to $104.

Price Target

Analyst Ratings

Morgan Stanley Maintains Overweight on American Electric Power, Lowers Price Target to $104

For decades, famed value investor&nbsp;Warren Buffett&nbsp;has insisted&nbsp;that he does not try to <a href="https://www.benzinga.com/personal-finance/24/04/38275323/warren-buffett-warns-dont-watch-the-market-closely-urges-not-to-obsessively-check-stock-prices-i">&#8220;time the market.&#8221;</a> But, his recent sales could serve as a warning sign for investors amid a period of protracted valuations.
What Happened: Buffett&#8217;s Berkshire Hathaway Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) has gradually wound down its largest positions over the last year.
Berkshire <a href="https://www.benzinga.com/markets/equities/24/11/41993666/warren-buffetts-berkshire-hathaway-slashes-apple-bofa-holdings-adds-dominos-pizza-in-q3">slashed its largest position</a> in Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) by over two-thirds since 2023. Buffett also sold much of his position in Bank of America Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) since the summer. He also trimmed back nearly all of his position in Ulta Beauty Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>), an atypically short holding period for the investor who preaches investing for the long term.
The Omaha, Nebraska-based company&#8217;s cash horde now stands at an astounding $325 billion.
See Also: <a href="https://www.benzinga.com/markets/equities/24/11/42137295/as-mstrs-michael-saylor-says-warren-buffett-is-destroying-berkshire-capital-analyst-suggests-ove">As MSTR&#8217;s Michael Saylor Says Warren Buffett Is &#8216;Destroying&#8217; Berkshire Capital, Analyst Suggests &#8216;Overpriced…Hot Stock Market&#8217; Could Be The Reason Oracle Of Omaha Is Sitting On $325B Cash</a>
Why it Matters: Several market experts have struggled to comprehend Buffett&#8217;s thought process — is he bearish on the market at large? Reallocating his portfolio away from Apple and Bank of America to diversify? Or, as Buffett hinted at in May, anticipating a future change to U.S. tax laws?
An <a href="https://www.bloomberg.com/opinion/articles/2024-11-21/buffett-s-325-billion-cash-hoard-is-an-early-warning-signal?srnd=homepage-americas">article</a> from Bloomberg columnist Nir Kaissar could fuel the first theory. A <a href="https://x.com/cullenroche/status/1859644225991987508">post</a> on X relayed a graph from the article showing Buffett&#8217;s cash pile conspicuously rising ahead of financial crises.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Interesting piece here from <a href="https://twitter.com/markets?ref_src=twsrc%5Etfw">@markets</a> and how Buffett's cash hoard often spikes before equity market slowdowns. &#x1f914;&#x1f914;&#x1f914; <a href="https://t.co/9aFmsMpP2N">pic.twitter.com/9aFmsMpP2N</a>
&mdash; Cullen Roche (@cullenroche) <a href="https://twitter.com/cullenroche/status/1859644225991987508?ref_src=twsrc%5Etfw">November 21, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<figcaption class="wp-element-caption">The company&#8217;s cash allocation ticked upwards ahead of two large market crashes in 2000 and 2008.</figcaption></figure>
As companies in the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) sustain a period of high valuations, Buffett could simply be heeding his advice, &#8220;to be fearful when&nbsp;others are greedy&nbsp;and to be greedy only when others are fearful,&#8221; allocating his portfolio away from what he deems riskier investments
Also Read:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42140842/sp-500-faces-volatile-2025-as-inflation-boom-could-return-bank-of-america-strategist">S&amp;P 500 Faces Volatile 2025 As &#8216;Inflation Boom&#8217; Could Return: Bank Of America Strategist</a></li>
</ul>
Photo: Shutterstock

Equities

AAPL

ULTA

Warren Buffett Claims To Not 'Time The Market,' But His Cash Horde Tells A Different Story

Jefferies analyst Brent Thill maintains Intuit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) with a Buy and raises the price target from $790 to $800.

INTU

Jefferies Maintains Buy on Intuit, Raises Price Target to $800

Morgan Stanley analyst Stephen Byrd maintains Ameren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEE#NYSE">AEE</a>) with a Equal-Weight and lowers the price target from $88 to $86.

Morgan Stanley Maintains Equal-Weight on Ameren, Lowers Price Target to $86

Halozyme Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) saw its shares rise on Friday after the company announced it was withdrawing its proposal to acquire Evotec SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) for 11 euro ($11.44) per share in cash, implying a fully <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42137175/halozyme-withdraws-proposal-to-acquire-evotec-following-evotecs-unwillingness-to-engage-in-discuss" rel="noreferrer noopener">diluted equity value of 2.0 billion euro.</a>
This move comes after prolonged efforts to engage with Evotec, which expressed its desire to remain independent, Halozyme said.
In addition to this, Halozyme reaffirmed its strong business outlook, with its 2024 guidance signaling continued growth.
The company expects revenue between $970 million and $1.02 billion ($1.003 billion) and an adjusted EBITDA range of $595 million to $625 million, reflecting significant double-digit growth.
Halozyme is confident in its ability to execute its strategy, with the goal of achieving ten approved products with ENHANZE by 2025 and $1 billion in royalty revenue by 2027.
Also Read: <a target="_blank" href="https://www.benzinga.com/economics/macro-economic-events/24/11/42141413/us-business-activity-soars-to-31-month-highs-in-november-small-caps-rally-dow-tops-44000" rel="noreferrer noopener">US Business Activity Soars To 31-Month Highs In November: Small Caps Rally, Dow Tops 44,000</a>
Helen Torley, CEO of Halozyme, explained that although the merger would have created a leading global pharma services company, Evotec was not open to further discussions.
Halozyme&#8217;s efforts to engage with Evotec&#8217;s leadership, including multiple requests for meetings, were unsuccessful, leading to the decision to withdraw the offer.
&#8220;A company spokesperson has publicly commented that its goal is to remain an independent company,&#8221; said Helen Torley,&nbsp;president and chief executive officer of Halozyme regarding Evotec, adding that &#8220;our multiple requests to meet were not accepted&#8221;.
&#8220;Evotec has taken notice of the statement made by Halozyme Therapeutics Inc. on 22 November, stating that it has withdrawn its non-binding proposal to acquire Evotec for EUR11.00 per share in cash,&#8221; Evotec <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/ac42141986/comment-on-withdrawn-non-binding-offer" rel="noreferrer noopener">said in a response.</a>
Price Action: HALO shares are trading higher by 6.21% to $48.54 at last check Friday, while EVO shares are down 18.8% to $4.345.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42137929/2025-us-economy-outlook-cloudier-than-normal-jpmorgan-says-boom-bust-scenarios" target="_blank" rel="noreferrer noopener">2025 US Economy Outlook&#8217; Cloudier Than Normal,&#8217; JPMorgan Says: Boom, Bust Scenarios</a></li>
</ul>

Movers

General

HALO

Halozyme Withdraws Evotec Bid After Rebuff, Reaffirms Strong Growth Outlook

Craig-Hallum analyst Richard Shannon maintains POET Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POET#NASDAQ">POET</a>) with a Buy and raises the price target from $3.5 to $5.5.

POET

Craig-Hallum Maintains Buy on POET Technologies, Raises Price Target to $5.5

Janney Montgomery Scott analyst Christopher Marinac upgrades National Bankshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKSH#NASDAQ">NKSH</a>) from Neutral to Buy and announces $38 price target.

Upgrades

NKSH

Janney Montgomery Scott Upgrades National Bankshares to Buy, Announces $38 Price Target

Craig-Hallum analyst Matthew Hewitt maintains Lifecore Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFCR#NASDAQ">LFCR</a>) with a Buy and raises the price target from $8 to $10.

LFCR

Craig-Hallum Maintains Buy on Lifecore Biomedical, Raises Price Target to $10

Craig-Hallum analyst Jeff Van Rhee maintains Cerence (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNC#NASDAQ">CRNC</a>) with a Hold and raises the price target from $3.5 to $6.

CRNC

Craig-Hallum Maintains Hold on Cerence, Raises Price Target to $6

DA Davidson analyst Peter Heckmann initiates coverage on CPI Card (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMTS#NASDAQ">PMTS</a>) with a Buy rating and announces Price Target of $36.

Initiation

PMTS

DA Davidson Initiates Coverage On CPI Card with Buy Rating, Announces Price Target of $36

Barrington Research analyst Gary Prestopino maintains PowerFleet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIOT#NASDAQ">AIOT</a>) with a Outperform and raises the price target from $10 to $15.

AIOT

Barrington Research Maintains Outperform on PowerFleet, Raises Price Target to $15

RBC Capital analyst Scott Hanold maintains Expand Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXE#NASDAQ">EXE</a>) with a Outperform and raises the price target from $102 to $116.

RBC Capital Maintains Outperform on Expand Energy, Raises Price Target to $116

IPOs

Trading Ideas

Ming Shing Group Shares Open For Trade At $5.65/Share; IPO Priced At $5.50/Share On 1.5M Shares

Canaccord Genuity analyst Susan Anderson maintains Waldencast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WALD#NASDAQ">WALD</a>) with a Buy and raises the price target from $5 to $6.

WALD

Canaccord Genuity Maintains Buy on Waldencast, Raises Price Target to $6

Macro Economic Events

Economics

Biden Administration Approves New York Plan To Launch $9 Congestion Fee Starting Jan. 5

RBC Capital analyst Rishi Jaluria reiterates Intuit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) with a Outperform and maintains $760 price target.

Reiteration

RBC Capital Reiterates Outperform on Intuit, Maintains $760 Price Target

During the last three months, 4 analysts shared their evaluations of Keros Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KROS#NASDAQ">KROS</a>), revealing diverse outlooks from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $87.25, with a high estimate of $100.00 and a low estimate of $76.00. Experiencing a 3.59% decline, the current average is now lower than the previous average price target of $90.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1732294863_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Keros Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Outperform</td>
<td>$77.00</td>
<td>-</td>
</tr>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>Announces</td>
<td>Buy</td>
<td>$96.00</td>
<td>-</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$76.00</td>
<td>$81.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Keros Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Keros Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Keros Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Keros Therapeutics's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/KROS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Keros Therapeutics analyst ratings.</a>
<h2>Unveiling the Story Behind Keros Therapeutics</h2>
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
<h3>Financial Insights: Keros Therapeutics</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Positive Revenue Trend: Examining Keros Therapeutics's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 4750.0% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Keros Therapeutics's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -13648.45%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -11.1%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Keros Therapeutics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -10.24%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Keros Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.04.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

KROS

Keros Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

Mini bonds have gained popularity among investors due to their affordability and accessibility.

Comments

Brookfield Finance Inc. 4.625% Subordinated Notes due October 16, 2080

Brookfield Finance Inc. 4.625% Subordinated Notes due October 16, 2080 (BNH) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga